Investing.com - Financial Markets Worldwide

Neuroone Medical Technologies Corp (NMTC)

NASDAQ
Currency in USD
0.887
-0.015(-1.66%)
Closed·
After Hours
0.920+0.033(+3.77%)
·

NMTC Financial Summary

Key Ratios

P/E Ratio-2.67
Price/Book16.53
Debt / Equity27.66%
Return on Equity-265.18%
Dividend Yield0.00%
EBITDA-11.64M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
30/09
2019
30/09
2020
30/09
2021
30/09
2022
30/09
2023
30/09
2024
30/09
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa1.930.242.123.413.45
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa-0.15-3.96-3.05-5.03-3.99
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa-4.9-10.22-10.03-11.96-11.89
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-13.64-9.95-10-11.86-12.32
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa4.767.9412.828.15.37
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa2.361.183.11.792.21
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa2.076.559.66.250.82
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa-4.65-5.07-4.18-8.86-6.72
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-3.43-8.6-7.52-12.89-11.01
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-0.12-0.07-3.242.65-0.12
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa7.3211.5312.027.47.27
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa3.782.861.26-2.84-3.86
* In Millions of USD (except for per share items)

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 1.450
(+63.47% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.07 / -0.09
Revenue / Forecast
1.40M / 2.40M
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Neuroone Medical's earnings for the latest quarter?

The Neuroone Medical EPS (TTM) is -0.22. Neuroone Medical reported sales of 1.39, net income of -2.27, and EPS of -0.07 for the latest quarter.

What was Neuroone Medical's net income for the latest quarter?

Neuroone Medical's net income for the latest quarter was -2.27.

How did Neuroone Medical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 3.27 in the previous quarter to 1.39 in the latest quarter, and net income moved from 1.79 to -2.27 compared to the previous quarter.

What is Neuroone Medical's net profit margin on a TTM basis?

Neuroone Medical's trailing twelve months (TTM) net profit margin is -356.74%.

How does Neuroone Medical's debt to equity ratio compare to industry standards?

Neuroone Medical's total debt-to-equity ratio is 27.66%.

What is Neuroone Medical's return on investment on a TTM basis?

Neuroone Medical's trailing twelve months (TTM) return on investment (ROI) is -265.18%.

Did Neuroone Medical gain or lose cash last quarter?

In the latest quarter, Neuroone Medical's net change in cash was 0.19 million.

What were Neuroone Medical's total assets and liabilities in the latest quarter?

As of the latest quarter, Neuroone Medical reported total assets of 4.46 million and total liabilities of 1.76 million.

How has Neuroone Medical's total revenue grown this year?

Neuroone Medical's total revenue was 3.27 in the previous quarter and 1.39 in the latest quarter.

What is Neuroone Medical's gross margin on a TTM basis?

Neuroone Medical's trailing twelve months (TTM) gross margin is -33.46%.

What was Neuroone Medical's revenue per share for the latest quarter?

Neuroone Medical's revenue per share for the latest quarter was 31.47.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.